A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus

Clinical Therapeutics

Volumn 25, Issue 7, 2003, Pages 2006-2021

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   Ciccarelli, Leonardina ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Candesartan; Diabetes mellitus; Hypertension; Insulin sensitivity; Perindopril

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CHOLESTEROL; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; VERTIGO;

EID: 0042703282     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80201-1     Document Type: Article

References (66)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation. 1979;59:8-13.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
3. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002;25:134-147.
4. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med. 1996;125:304-310.
5. Aromaa A, Reunanen A, Pyorala K. Hypertension and mortality in diabetic and non-diabetic Finnish men. J Hypertens Suppl. 1984;2(Suppl):S205-S207.
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
7. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175-1179.
8. Parving HH, Smidt UM. Hypotensive therapy reduces microvascular albumin leakage in insulin-dependent diabetic patients with nephropathy. Diabet Med. 1986;3:312-315.
9. Bakris GL. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 1993;6(Suppl):140S-147S.
10. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet. 1998;351:689-690.
11. Pahor M, Psaty BM, Furberg CD. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. J Cardiovasc Pharmacol. 1998;32(Suppl 2):S18-S23.
12. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
13. Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med. 1998;105(Suppl 1A):27S-31S.
14. Gavras I, Gavras H. Metabolic effects of angiotensin-converting enzyme inhibition: The role of bradykinin. Curr Opin Endocrinol Diabetes. 2002;9:323-328.
15. Gradman AH. AT(1)-receptor blockers: Differences that matter. J Hum Hypertens. 2002;16(Suppl 3):S9-S16
16. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother. 1998;32:1060-1066.
17. Feldman R. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X. Can J Cardiol. 2000;16(Suppl E):41E-44E.
18. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
19. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995;26:869-879.
20. Sowers JR, Epstein M. Diabetes mellitus and hypertension, emerging therapeutic perspectives. Cardiovasc Drug Rev. 1995;13:149-210.
21. Sowers JR. Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Nephrol Dial Transplant. 1995;10(Suppl 9): 52-55
22. Lee AF, Struthers AD. The impact of angiotensin converting enzyme inhibitors on the arterial wall. Vase Med. 1996;1:109-113.
23. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
24. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
25. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
26. Viberti G, Wheeldon NM. Microalbuminuna reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002;106:672-678
27. American Diabetes Association. Screening for diabetes. Diabetes Care. 2001;24(Suppl 1):S21-S24.
28. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-183.
29. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080-1084.
30. Steiness IB. Vibratory perception in diabetics during arrested blood flow to the limb. Acta Med Scand. 1959;163:195-205.
31. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999;16:716-730.
32. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia. 1972;8:260-266.
33. Bunn HE, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science. 1978;200:21-27.
34. Klose S, Borner K. Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA-II) [in German]. J Clin Chem Clin Biochem. 1978;15:121-130.
35. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU, ed. Methods of Enzymatic Analysis. 2nd English ed. New York: Academic Press; 1974:18-31.
36. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultra-centrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
37. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502
38. Leblond L, Marcel YL. The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for binding of high density lipoproteins to HepG2 cells. J Biol Chem. 1991;266:6058-6067.
39. De Loof H, Rosseneu M, Yang CY, et al. Human apolipoprotein B: Analysis of internal repeats and homology with other apolipoproteins. J Lipid Res. 1987;28:1455-1465.
40. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol. 1992;2:427-438.
41. Scanu AM, Scandiani L. Lipoprotein(a): Structure, biology, and clinical relevance. Adv Intern Med. 1991;36:249-270
42. Utermann G, Weber W. Protein composition of lipoprotein(a). J Clin Invest. 1987;80:458-465.
43. Araki A, Sako Y. Determination of flee and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
44. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
45. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York: McGraw-Hill; 1971.
46. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19:403-418.
47. Lees KR, Reid JL. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man. Br J Clin Pharmacol. 1987;23:159-164.
48. Littler WA, West JW. Twenty-four hour action of ACE inhibitors. J Hum Hypertens. 1990;4(Suppl 4):13-16.
49. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens. 1997;11(Suppl 2):S49-S53.
50. Belcher G, Hubner R, George M, et al. Candesartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens. 1997;11 (Suppl 2):S85-S89.
51. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
52. Kuperstein R, Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives. Circulation. 2000;102:1802-1806.
53. Seedat YK, Randeree IGH. Antihypertensive effect and tolerability of perindopril in Indian hypertensive and type 2 diabetic patients. 1-Year randomised, double-blind, parallel study vs atenolol. Clin Drug Invest. 1998;16:229-240.
54. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15:316-320.
55. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens. 1997;11(Suppl 2):S81-S83.
56. Donnelly R. Angiotensin-converting enzyme inhibitors and insulin sensitivity: Metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol. 1992;20(Suppl 11):S38-S44.
57. Fogari R, Zoppi A. Benefits of the bradykinins beyond blood pressure control: Insulin sensitivity and thrombogenesis. Eur Heart J. 2000;2(Suppl H):H7-H13.
58. Fogari R, Zoppi A, Corradi L, et al. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non-diabetic hypertensive patients. Br J Clin Pharmacol. 1998;46:467-471.
59. Higashiura K, Ura N, Miyazaki Y, Shimamoto K. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens. 1999;13(Suppl 1):S71-S74.
60. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI(0,120)): Comparison with other measures. Diabetes Res Clin Pract. 2000;47:177-184.
61. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
62. Berne C. Metabolic effects of ACE inhibitors. J Intern Med. 1991;735(Suppl):119-125.
63. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36:272-279.
64. Derosa G, Mugellini A, Ciccarelli L, et al. Effects of fosinopril on blood pressure, lipid profile, and lipoprotein(a) levels in normotensive patients with type 2 diabetes and microalbuminuria: An open-label, uncontrolled study. Curr Ther Res Clin Exp. 2002;63:216-226.
65. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999;34:285-290.
66. Sheu WH, Lee WJ, Chen YT. Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects. Am J Hypertens. 2000;13:14-20.